1887

Abstract

Cells in which the appropriate viral receptor cannot be detected may paradoxically act as a host to the virus. For example, RD cells are often considered to be non-permissive for infection with coxsackievirus and adenovirus receptor (CAR)-dependent group B coxsackieviruses (CVB), insofar as inoculated cell monolayers show little or no cytopathic effect (CPE) and immunohistological assays for CAR have been consistently negative. Supernatants recovered from RD cells exposed to CVB, however, contained more virus than was added in the initial inoculum, indicating that productive virus replication occurred in the monolayer. When infected with a recombinant CVB type 3 (CVB3) chimeric strain expressing S-Tag within the viral polyprotein, 4–11 % of RD cells expressed S-Tag over 48 h. CAR mRNA was detected in RD cells by RT-PCR, and CAR protein was detected on Western blots of RD lysates; both were detected at much lower levels than in HeLa cells. Receptor blockade by an anti-CAR antibody confirmed that CVB3 infection of RD cells was mediated by CAR. These results show that some RD cells in the culture population express CAR and can thereby be infected by CVB, which explains the replication of CAR-dependent CVB in cell types that show little or no CPE and in which CAR has not previously been detected. Cells within cultures of cell types that have been considered non-permissive may express receptor transiently, leading to persistent replication of virus within the cultured population.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82710-0
2007-11-01
2024-12-12
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/11/3031.html?itemId=/content/journal/jgv/10.1099/vir.0.82710-0&mimeType=html&fmt=ahah

References

  1. Argo E., Gimenez B., Cash P. 1992; Non-cytopathic infection of rhabdomyosarcoma cells by coxsackie B5 virus. Arch Virol 126:215–219 [CrossRef]
    [Google Scholar]
  2. Bergelson J. M., Mohanty J. G., Crowell R. L., St John N. F., Lublin D. M., Finberg R. W. 1995; Coxsackievirus B3 adapted to growth in RD cells binds to decay accelerating factor (CD55). J Virol 69:1903–1906
    [Google Scholar]
  3. Bergelson J. M., Modlin J. F., Wieland-Alter W., Cunningham J. A., Crowell R. L., Finberg R. W. 1997; Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors. J Infect Dis 175:697–700 [CrossRef]
    [Google Scholar]
  4. Carson S. D. 2000; Limited proteolysis of the coxsackievirus and adenovirus receptor (CAR) on HeLa cells exposed to trypsin. FEBS Lett 484:149–152 [CrossRef]
    [Google Scholar]
  5. Carson S. D. 2004; Coxsackievirus and adenovirus receptor (CAR) is modified and shed in membrane vesicles. Biochemistry 43:8136–8142 [CrossRef]
    [Google Scholar]
  6. Carson S. D., Hobbs J. T., Tracy S. M., Chapman N. M. 1999; Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells: regulation in response to cell density. J Virol 73:7077–7079
    [Google Scholar]
  7. Chapman N. M., Kim K. S., Tracy S., Jackson J., Hofling K., Leser J. S., Malone J., Kolbeck P. 2000; Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. J Virol 74:7952–7962 [CrossRef]
    [Google Scholar]
  8. Cunningham K. A., Chapman N. M., Carson S. D. 2003; Caspase-3 activation and ERK phosphorylation during CVB3 infection of cells: influence of the coxsackievirus and adenovirus receptor and engineered variants. Virus Res 92:179–186 [CrossRef]
    [Google Scholar]
  9. Domingo E., Martin V., Perales C., Grande-Perez A., Garcia-Arriaza J., Arias A. 2006; Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol 299:51–82
    [Google Scholar]
  10. Excoffon K. J. D. A., Gansemer N., Traver G., Zabner J. 2007; Functional effects of coxsackievirus and adenovirus receptor glycosylation on homophilic adhesion and adenoviral infection. J Virol 81:5573–5578 [CrossRef]
    [Google Scholar]
  11. Feuer R., Mena I., Pagarigan R., Slifka M. K., Whitton J. L. 2002; Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol 76:4430–4440 [CrossRef]
    [Google Scholar]
  12. Hofling K., Tracy S., Chapman N., Kim K. S., Leser J. S. 2000; Expression of an antigenic adenovirus epitope in a group B coxsackievirus. J Virol 74:4570–4578 [CrossRef]
    [Google Scholar]
  13. Hsu K. H., Lonberg-Holm K., Alstein B., Crowell R. L. 1988; A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol 62:1647–1652
    [Google Scholar]
  14. Kim K. S., Tracy S., Tapprich W., Bailey J., Lee C. K., Kim K., Barry W. H., Chapman N. M. 2005; 5′-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. J Virol 79:7024–7041 [CrossRef]
    [Google Scholar]
  15. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 [CrossRef]
    [Google Scholar]
  16. Polacek C., Ekstrom J.-O., Lundgren A., Lindberg A. M. 2005; Cytolytic replication of coxsackievirus B2 in CAR-deficient rhabdomyosarcoma cells. Virus Res 113:107–115 [CrossRef]
    [Google Scholar]
  17. Raines R. T., McCormick M., Van Oosbree T. R., Mierendorf R. C. 2000; The S.Tag fusion system for protein purification. Methods Enzymol 326:362–376
    [Google Scholar]
  18. Reagan K. J., Goldberg B., Crowell R. L. 1984; Altered receptor specificity of coxsackievirus B3 after growth in rhabdomyosarcoma cells. J Virol 49:635–640
    [Google Scholar]
  19. Schmidtke M., Selinka H.-C., Heim A., Jahn B., Tonew M., Kandolf R., Stelzner A., Zell R. 2000; Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences in capsid protein VP1. Virology 275:77–88 [CrossRef]
    [Google Scholar]
  20. Seidman M. A., Hogan S. M., Wendland R. L., Worgall S., Crystal R. G., Leopold P. L. 2001; Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle. Mol Ther 4:13–21 [CrossRef]
    [Google Scholar]
  21. Shafren D. R., Williams D. T., Barry R. D. 1997; A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J Virol 71:9844–9848
    [Google Scholar]
  22. She R. C., Crist G., Billetdeaux E., Langer J., Petti C. A. 2006; Comparison of multiple shell vial cell lines for isolation of enteroviruses: a national perspective. J Clin Virol 37:151–155 [CrossRef]
    [Google Scholar]
  23. Shieh J. T. C., Bergelson J. M. 2002; Interaction with decay-accelerating factor facilitates coxsackievirus B infection of polarized epithelial cells. J Virol 76:9474–9480 [CrossRef]
    [Google Scholar]
  24. Tomko R. P., Xu R., Philipson L. 1997; HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 94:3352–3356 [CrossRef]
    [Google Scholar]
  25. Tracy S., Chapman N. M., Tu Z. 1992; Coxsackievirus B3 from an infectious cDNA copy of the genome is cardiovirulent in mice. Arch Virol 122:399–409 [CrossRef]
    [Google Scholar]
  26. Tracy S., Drescher K. M., Chapman N. M., Kim K. S., Carson S. D., Pirruccello S., Lane P. H., Romero J. R., Leser J. S. 2002; Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. J Virol 76:12097–12111 [CrossRef]
    [Google Scholar]
  27. Tu Z., Chapman N. M., Hufnagel G., Tracy S., Romero J. R., Barry W. H., Zhao L., Curry K., Shapiro B. 1995; The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the 5′ nontranslated region. J Virol 69:4607–4618
    [Google Scholar]
  28. Zolotukhin S., Potter M., Hauswirth W. W., Guy J., Muzyczka N. 1996; A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70:4646–4654
    [Google Scholar]
/content/journal/jgv/10.1099/vir.0.82710-0
Loading
/content/journal/jgv/10.1099/vir.0.82710-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error